Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]
Awaiting development
Reference number: GID-TA11769
Expected publication date: TBC
To appraise the clinical and cost effectiveness of Sacituzumab govitecan within its marketing authorisation for treating hormone
receptor-positive HER2-negative advanced breast cancer